Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Publisher's site:
http://dx.doi.org/10.15585/mmwr.mm7109e2
Personal Author:
Hause, Anne M. ; Baggs, James ; Marquez, Paige ; Abara, Winston E. ; Olubajo, Babatunde ; ... More +
Hause, Anne M. ; Baggs, James ; Marquez, Paige ; Abara, Winston E. ; Olubajo, Babatunde ; Myers, Tanya R. ; Su, John R. ; Thompson, Deborah ; Gee, Julianne ; Shimabukuro, Tom T. ; Shay, David K. Less -
Description:
As of February 20, 2022, only BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine has been authorized for use in persons aged 12-17 years in the United States (1). The Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for Pfizer-BioNTech vaccine on December 9, 2021, to authorize a homologous* booster dose for persons aged 16-17 years ≥6 months after receipt of dose 2 (1). On January 3, 2022, authorization was expanded to include persons aged 12-15 years, and for all persons aged ≥12 years, the interval between dose 2 and booster dose was shortened to ≥5 months (1). To characterize the safety of Pfizer-BioNTech booster doses among persons aged 12-17 years (adolescents), CDC reviewed adverse events and health impact assessments during the week after receipt of a homologous Pfizer-BioNTech booster dose reported to v-safe, a voluntary smartphone-based safety Surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety Surveillance system managed by CDC and FDA. During December 9, 2021-February 20, 2022, approximately 2.8 million U.S. adolescents received a Pfizer-BioNTech booster dose.| During this period, receipt of 3,418 Pfizer-BioNTech booster doses were reported to v-safe for adolescents. Reactions were reported to v-safe with equal or slightly higher frequency after receipt of a booster dose than after dose 2, were primarily mild to moderate in severity, and were most frequently reported the day after vaccination. VAERS received 914 reports of adverse events after Pfizer-BioNTech booster dose vaccination of adolescents; 837 (91.6%) were nonserious and 77 (8.4%) were serious. Health care providers, parents, and adolescents should be advised that local and systemic reactions are expected among adolescents after homologous Pfizer-BioNTech booster vaccination, and that serious adverse events are rare.
Subject:
[+]
Adolescent Adverse Drug Reaction Reporting Systems BNT162 Vaccine Child COVID-19 Vaccines Female Humans Immunization, Secondary Male Patient Safety
Source:
MMWR Morb Mortal Wkly Rep. 71(9):347-351
Pubmed ID:
35239637
Pubmed Central ID:
PMC8893335
Document Type:
Journal Article
Place as Subject:
United States
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:305f3cd30b25fefdc4fee8607de45c36a0b8614e7647758fa58e57b6b2e3c387
Download URL:
https://stacks.cdc.gov/view/cdc/115830/cdc_115830_DS1.pdf
File Type:

Supporting Files

• 	mm7109e2-F.gif	gif
  	mm7109e2-F.jpg	jpeg
  	mm7109e2.nxml	xml

More +